The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats.
In anesthetized cats the dopamine autoreceptor agonist B-HT 920 (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepine), 1 mg/kg i.v., greatly decreased the amount of dopamine in cerebroventricular perfusates. This effect was antagonized by a low dose (50 micrograms/kg i.v.) of haloperidol, but not by the alpha 2-adrenoceptor blocker idazoxan. Our observations provide evidence that B-HT 920 inhibits brain dopamine release in vivo and may be therapeutically valuable in diseases presumed to be accompanied by a predominance of brain dopamine activity, such as Huntington's disease, mania and schizophrenia.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000758:Anesthesia; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D002415:Cats; D002552:Cerebral Ventricles / Q000378:metabolism*; D004146:Dioxanes / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D019329:Idazoxan; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*
D000316:Adrenergic alpha-Agonists; D001381:Azepines; D004146:Dioxanes; D011954:Receptors, Dopamine; C024763:talipexole; D006220:Haloperidol; D004298:Dopamine; D019329:Idazoxan